BEAT - BioTelemetry, Inc.
| Previous Close | 33.90 |
| Open | 33.75 |
| Bid | 28.05 x 100 |
| Ask | 35.65 x 100 |
| Day's Range | 33.65 - 34.65 |
| 52 Week Range | 23.30 - 39.20 |
| Volume | 176,095 |
| Avg. Volume | 377,315 |
| Market Cap | 1.129B |
| Beta | 0.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.53 |
| Earnings Date | May 1, 2018 - May 7, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.00 |
- GlobeNewswire•2 days ago
BioTelemetry, Inc. to Release First Quarter 2018 Earnings Results on April 25, 2018
MALVERN, Pa., April 19, 2018-- BioTelemetry, Inc. will release its first quarter 2018 earnings on Wednesday, April 25 at 4:00 PM Eastern Time.. The BioTelemetry quarterly conference call will be held at ...
American City Business Journals•11 days agoHealthcare and biotech investor Sami Hamade dies
Hamade had spent the past three-plus years as a partner with New York-based Apple Tree Partners.
- Thomson Reuters StreetEvents•25 days ago
Edited Transcript of BEAT earnings conference call or presentation 22-Feb-18 10:00pm GMT
Q4 2017 BioTelemetry Inc Earnings Call
- GlobeNewswire•28 days ago
BioTelemetry, Inc. (Nasdaq: BEAT) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its 10th Listing Anniversary
What: BioTelemetry, Inc. will visit the Nasdaq MarketSite in Times Square in celebration of its 10th listing anniversary. BioTelemetry, Inc. is the leading wireless medical technology company focused on ...
Market Realist•last monthWhat Analysts Recommend for Amedisys and Peers in March 2018
Amedisys (AMED) is a healthcare services company with a focus on providing home care through three segments: home health, hospice, and personal care. Of the 11 analysts covering Amedisys in March 2018, three analysts have given the stock a “strong buy” rating. Two analysts have given the stock a “buy” rating, while six analysts have given it a “hold” rating.
Market Realist•last monthA Look at BioTelemetry’s Financial Performance
Here's What's in Store for BioTelemetry in 2018
Market Realist•last monthUnderstanding BioTelemetry’s Business Strategy
BioTelemetry’s (BEAT) business strategy is to solidify its position as a leading provider of outpatient cardiac monitoring services, expand in the research market, and leverage its monitoring platform in new markets. In order to increase the demand for its portfolio of outpatient cardiac monitoring solutions, BioTelemetry is focusing on educating cardiologists, electrophysiologists, and neurologists on the benefits of using mobile cardiac telemetry for arrhythmia monitoring while stressing the increased diagnostic yield and ability to deliver more effective treatments.
Market Realist•last monthAnalyst Ratings for BioTelemetry and Its Peers in March 2018
BioTelemetry (BEAT) provides monitoring services and digital population health management for healthcare providers, medical device manufacturing, and centralized core laboratory services for clinical research. In July 2017, BioTelemetry acquired LifeWatch, a supplier of mobile cardiac monitoring solutions. The acquisition is expected to help BioTelemetry create a comprehensive connected healthcare platform and deliver solutions in the market more effectively.
Market Realist•last monthExploring BioTelemetry’s Segments
BioTelemetry (BEAT) operates in three segments: healthcare, research, and technology. The healthcare segment contributed 81% of BioTelemetry’s total revenues in fiscal 2017. Under this segment, BioTelemetry offers a full spectrum of solutions with a single source of cardiac monitoring services to cardiologists, electrophysiologists, neurologists, and primary care physicians.
- Zacks•2 months ago
BioTelemetry (BEAT) Beats Q4 Earnings and Revenue Estimates
BioTelemetry (BEAT) sees strong Q4 results, courtesy of solid acquisitions and promising performance by the MCT platform.
- GlobeNewswire•2 months ago
Analysis: Positioning to Benefit within Bluerock Residential Growth REIT, National Presto Industries, Healthways, Deluxe, BioTelemetry, and Modine Manufacturing — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, March 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- ACCESSWIRE•2 months ago
Free Research Report as LabCorp's Revenue Jumped 13.2%; Adjusted EPS Advanced 14%
Stock Monitor: BioTelemetry Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 1, 2018 / Active-Investors.com has just released a free earnings report on Laboratory Corp. of America Holdings (NYSE: ...
- ACCESSWIRE•2 months ago
Blog Exposure - PerkinElmer to Takeover Australian Biotech Company RHS Ltd
Stock Monitor: BioTelemetry Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 28, 2018 / Active-Investors.com has just released a free research report on PerkinElmer, Inc. (NYSE: PKI ). If you ...
- GuruFocus.com•2 months ago
BioTelemetry Inc (BEAT) Files 10-K for the Fiscal Year Ended on December 31, 2017
BioTelemetry Inc (NASDAQ:BEAT) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
- Associated Press•2 months ago
BioTelemetry reports 4Q loss
The Malvern, Pennsylvania-based company said it had a loss of 48 cents per share. Earnings, adjusted for non-recurring costs, came to 32 cents per share. The results exceeded Wall Street expectations. ...
- GlobeNewswire•2 months ago
BioTelemetry, Inc. Reports Fourth Quarter 2017 Financial Results
Company Delivers Record Revenue and Adjusted EBITDA Exceeds Expectations. MALVERN, Pa., Feb. 22, 2018-- BioTelemetry, Inc., the leading mobile and wireless medical technology company focused on the delivery ...
- Benzinga•2 months ago
BioTelemetry Q4 Earnings Preview
On Thursday, BioTelemetry (NASDAQ: BEAT ) will release its latest earnings report. Here is Benzinga's outlook for the company. Earnings and Revenue Based on BioTelemetry management projections, analysts ...
- GlobeNewswire•2 months ago
BioTelemetry, Inc. to Release Fourth Quarter 2017 Earnings Results on February 22, 2018
MALVERN, Pa., Feb. 12, 2018-- BioTelemetry, Inc. will release its fourth quarter 2017 earnings on Thursday, February 22 nd at 4:00 PM Eastern Time.. The BioTelemetry quarterly conference call will be held ...
- ACCESSWIRE•3 months ago
Favorable Regulatory Trends & Recent FDA Clearance Indicate Big Returns For BTCY Shareholders in 2018
Government bodies like Medicare, Medicaid and the U.S. FDA are signaling that remote patient monitoring is going to be a huge industry over the coming decade; agencies improving the environment for medical ...
- Capital Cube•4 months ago
ETFs with exposure to BioTelemetry, Inc. : December 29, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioTelemetry, Inc. Here are 5 ETFs with the largest exposure to BEAT-US. Comparing the performance and risk of BioTelemetry, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Capital Cube•4 months agoBioTelemetry, Inc. :BEAT-US: Earnings Analysis: Q3, 2017 By the Numbers : December 28, 2017
Categories: Yahoo FinanceGet free summary analysis BioTelemetry, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of BioTelemetry, Inc. – iRadimed Corp, Neovasc Inc. and InfuSystem Holdings, Inc. (IRMD-US, NVCN-US and INFU-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 81.02 ... Read more (Read more...)
- Investor's Business Daily•4 months ago
Stocks Showing Improved Relative Strength: BioTelemetry
BioTelemetry shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
- Capital Cube•4 months ago
BioTelemetry, Inc. – Value Analysis (NASDAQ:BEAT) : December 15, 2017
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives BioTelemetry, Inc. a score of 72. Our analysis is based on comparing BioTelemetry, Inc. with the following peers – NuVasive, Inc., iRadimed Corp, Neovasc Inc. and InfuSystem Holdings, Inc. (NUVA-US, IRMD-US, NVCN-US and INFU-US). Investment Outlook BioTelemetry, Inc. has a fundamental score of 72 and has a ... Read more (Read more...)
